Chronic low back pain (CLBP) is a leading cause of disability globally, affecting millions and posing significant challenges to healthcare systems due to its complex aetiology and limited effective treatments (Gilligan et al., 2021). Recent research has sparked debate by suggesting that low-grade bacterial infections, particularly involving Cutibacterium acnes (C. acnes), may contribute to CLBP…
Persica Pharmaceuticals has developed PP353, an intradiscal injection designed to treat chronic low back pain linked to bacterial infections, particularly cases associated with Modic changes (pathological alterations in vertebrae seen on MRI). PP353 combines: Recent Study & Findings Potential Impact
Last week I picked up a copy of Metro and came across an article entitled “Back pain ‘cured with a £114 dose of antibiotics’”. The story has also been covered by theguardian, The Times and the NHS. It’s based on the results of 2 studies published in the European Spine Journal by Hanne B Albert…